Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents  

作　　者：LIU Xingchen WANG Xiaobing 

机构地区：[1]Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines,School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 210009,China

出　　处：《Chinese Journal of Natural Medicines》2022年第11期814-829,共16页中国天然药物（英文版）

基　　金：supported by the Natural Science Foundation of Jiangsu Province(No.BK20201332);the“Double First-Class”University Project(No.CPU2018GF03);the Six Talent Peaks Project of Jiangsu Province(No.SWYY-107);Jiangsu Province‘333’Project,111 Center from Ministry of Education of China and the State Administration of Foreign Experts Affairs of China(No.B18056).

摘　　要：Parthenolide(PTL)is a sesquiterpene lactone derived from medicinal plant feverfew(Tanacetum parthenium).Recent studies have demonstrated that it has multiple pharmacological activities,especially in the treatment of various hematological and solid cancers.The superior anticancer activity of PTL suggests that it has the potential to be a first-line drug.However,due to the limited physical and chemical properties,as well as bioavailability,structural modification strategies are strongly recommended to improve the anticancer activity.This review describes representative PTL derivatives obtained by different modification strategies,which are reported to exert antiproliferative activities superior to the parent compound PTL.Furthermore,we also summarize their basic mechanisms on cancer-related signaling pathways,so as to explain the potential and characteristics of PTL and its derivatives in cancer therapy.

关 键 词：PARTHENOLIDE DERIVATIVES Structural modification Anticancer mechanisms 

分 类 号：R284[医药卫生—中药学]